Shuichi Hironaka

18PUBLICATIONS
44CO-AUTHORS
Cancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Mar 15, 2026
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Takeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka

|Jan 27, 2026
Two cases of metastatic colorectal cancer in which epidermal growth factor receptor gene amplification benefited from panitumumab monotherapy.

Taro Sato, Fumio Nagashima, Naohiro Okano

|May 16, 2025
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.

Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama

|Apr 02, 2025
Systemic therapy for pretreated advanced biliary tract cancer: past developments and recent advances.

Naohiro Okano, Angelo Pirozzi, Oluseyi Abidoye

|Mar 25, 2025
A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G).

Nozomu Machida, Takehiro Okumura, Narikazu Boku

|Dec 31, 2024
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.

Azusa Komori, Shuichi Hironaka, Shigenori Kadowaki

Pageof 3

Frequent Collaborators

3 joint publications

Narikazu Boku

2 joint publications

Ichinosuke Hyodo

2 joint publications

Ken Kato

2 joint publications

Takashi Kojima